Study of Cidabenamine and Azacitidine as Maintenance Treatment to Prevent Progression in High-Risk Peripheral T-Cell Lymphoma After Stem Cell Transplant

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining Cidabenamine with Azacitidine as maintenance therapy after allogeneic peripheral blood hematopoietic stem cell transplantation in patients with high-risk peripheral T-cell lymphoma. This phase II clinical trial aims to prevent disease progression in this group of patients. The study is conducted at a single center and plans to enroll 40 patients, focusing on those meeting specific high-risk criteria and transplant conditions. Participants will receive the combination of Cidabenamine and Azacitidine following their transplant. Before treatment, patients will undergo screening including consent, eligibility verification, and collection of demographic and medical history data. Assessments such as vital signs, physical exams, PET-CT scans, bone marrow tests, flow cytometry, lymphoid gene rearrangement analysis, and bone marrow pathology will be performed to monitor health and disease status. Throughout the study, researchers will track overall survival up to 2 years as the primary outcome. Secondary outcomes include progression-free survival, non-relapse mortality, and relapse rates within 1 to 2 years. Patients will be closely monitored for treatment responses and safety. The total participation duration spans from screening through follow-up assessments, allowing comprehensive evaluation of the maintenance therapys impact.

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma